Research programme: nitroxyl-based cardiovascular therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: nitroxyl-based cardiovascular therapeutics - Bristol-Myers Squibb

Alternative Names: CXL-1036; HNO donors - Bristol-Myers Squibb; HNO prodrugs - Bristol-Myers Squibb; nitroxyl donors - Bristol-Myers Squibb

Latest Information Update: 14 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardioxyl Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Nitrogen oxides; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic heart failure; Pulmonary arterial hypertension

Most Recent Events

  • 08 Dec 2015 Cardioxyl Pharmaceuticals has been acquired and merged into Bristol-Myers Squibb
  • 20 Nov 2014 Preclinical pharmacodynamics data in Chronic heart failure presented at the 87th Annual Scientific Sessions of the American Heart Association (AHA-2014)
  • 16 Sep 2014 Preclinical trials in Chronic heart failure in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top